Latest H5N1 clinical trials Stories

SAN FRANCISCO, Sept. 8 /PRNewswire/ -- Vaxart, Inc., a San Francisco biotechnology company developing oral-delivery vaccines, has been awarded a $2.8 million phase II Small Business Innovation Research grant from the National Institute of Allergy and Infectious Disease (National Institutes of Health) to support development of its first product, an orally-delivered vaccine for H5N1 Avian influenza. "We thank the NIH for funding the further safety and efficacy tests, which, along with our...

BOZEMAN, Mont., Sept 8 /PRNewswire/ -- LigoCyte Pharmaceuticals, Inc. announced today that it has initiated its third human clinical trial of its norovirus vaccine. The Phase I/II study will assess safety and immunogenicity associated with LigoCyte's investigational, nasally-delivered, dry powder vaccine in healthy adults. The study will also assess potential protection against clinical symptoms of norovirus infection by including a live virus challenge of subjects that have received...

BEIJING, Aug. 28 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE: SVA), a leading provider of biopharmaceutical products in China, announced today that the Beijing Public Health Bureau has selected Sinovac as one of the four manufacturers to supply Anflu(R), Sinovac's seasonal influenza vaccine, for the benefit of the citizens of Beijing. The Beijing Public Health Bureau completed the bidding process for the purchase of flu vaccines and corresponding services for 2009 on August 26,...

U.S. researchers said on Tuesday that tobacco plants might yield a cheap and easy-to-administer vaccine against a pesky stomach virus called norovirus, Reuters reported.They found that tobacco can produce a protein that can be used to make a nasal vaccine against norovirus, which causes diarrhea and vomiting, particularly in settings where many people share limited space.Charles Arntzen, a plant biologist at Arizona State University, told a news conference at a meeting of the American...

The U.S. subsidiary of a British drug company is signing up volunteers for clinical trials of its swine flu vaccine, the company says. MedImmune plans to run two U.S. vaccine trials simultaneously, one on children ages 3 to 17 and another for adults 18-49, Washington Business Journal reported Wednesday. If everything works well, we are expected to have our first doses ready by the end of October, said Perla Copernik, a spokeswoman for MedImmune, a subsidiary of AstraZeneca PLC in London....

BEIJING, Aug. 18 /PRNewswire-Asia/ -- Sinovac Biotech Ltd. (NYSE Amex: SVA), a leading provider of vaccines in China, announced today positive top-line results from the completed clinical trial for its internally-developed H1N1 vaccine. The clinical data unblinding conference was held in Beijing on the afternoon of August 17, 2009. Notably, Sinovac is the first company worldwide to complete clinical trials for the H1N1 vaccine. The analysis of the clinical trial results showed that...

On Friday, GlaxoSmithKline PLC, the drugmaker of a new swine flu vaccine, said that it has started to test the vaccine in humans. Glaxo said it is planning 16 clinical trials of its swine flu vaccine in over 9,000 people in Europe and North America.  The company expects to see results in September from its first trial in Germany.  The data will be shared with drug regulators so they will be able to decide whether to license the vaccine or not. The U.S. and Europe both have fast-track...

LYON, France and SWIFTWATER, Pa., Aug. 7 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of the sanofi-aventis Group (EURONEXT: SAN and NYSE: SNY), announced today the company has submitted to the U.S. Food and Drug Administration (FDA) a supplemental application for licensure of its influenza A(H1N1) 2009 monovalent vaccine. Responding to recent recommendations by the FDA, the company's supplemental application requests the FDA's evaluation of the influenza A(H1N1) 2009 strain...

World Health Organization officials in Switzerland said manufacturers are expected to deliver the first doses of pandemic H1N1 flu vaccine in September. Dr. Marie-Paule Kieny, director of the WHO initiative for vaccine research said yields of antigen -- the crucial component in vaccine production -- are larger than companies had expected, the Los Angeles Times reported. I don't want to say too early that the question has been resolved, but it really seems like we have found a way to go...

The World Health Organization stated on Thursday that the procedures being implemented to speed approvals of the new vaccines for the swine flu do not reduce safety.According to the WHO, vaccines have to be readily accessible and available in large amounts to have the greatest impact. "The public needs to be reassured that regulatory procedures in place for the licensing of pandemic vaccines, including procedures for expediting regulatory approval, are rigorous and do not compromise...